No profile data available.
Savara Inc. (SVRA) is a healthcare company in the lung treatment pharmaceuticals industry, based in Yardley, United States, with about 70 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$118.84 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $1.01 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc.
Savara reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$1.01 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (lung treatment pharmaceuticals) include Vertex Pharmaceuticals Incorporated (VRTX), Innoviva, Inc. (INVA), Upstream Bio, Inc. (UPB), Gyre Therapeutics, Inc. (GYRE).